A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)

20250 citationsJournal Articlegold Open Access

Authors

No added clinical benefit of berzosertib and topotecan combination was observed over topotecan monotherapy in patients with platinum-resistant SCLC.

Published in: ESMO Open

Volume 11, Issue 1, pp. 105918-105918

Field-Weighted Citation Impact: 0.00